NO20016187L - Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister - Google Patents

Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister

Info

Publication number
NO20016187L
NO20016187L NO20016187A NO20016187A NO20016187L NO 20016187 L NO20016187 L NO 20016187L NO 20016187 A NO20016187 A NO 20016187A NO 20016187 A NO20016187 A NO 20016187A NO 20016187 L NO20016187 L NO 20016187L
Authority
NO
Norway
Prior art keywords
benzhydryl
azabicyclo
polymorphs
methoxybenzyl
oct
Prior art date
Application number
NO20016187A
Other languages
English (en)
Other versions
NO20016187D0 (no
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Michael Jon Gumkowski
David Joseph Muehlbauer
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20016187L publication Critical patent/NO20016187L/no
Publication of NO20016187D0 publication Critical patent/NO20016187D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20016187A 1999-06-22 2001-12-18 Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister NO20016187D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22
PCT/IB2000/000756 WO2000078759A1 (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016187L true NO20016187L (no) 2001-12-18
NO20016187D0 NO20016187D0 (no) 2001-12-18

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016187A NO20016187D0 (no) 1999-06-22 2001-12-18 Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister

Country Status (35)

Country Link
US (1) US6262067B1 (no)
EP (1) EP1187834A1 (no)
JP (1) JP2003502425A (no)
KR (1) KR20020030280A (no)
CN (1) CN1390216A (no)
AP (1) AP2001002367A0 (no)
AR (1) AR024411A1 (no)
AU (1) AU767336B2 (no)
BG (1) BG106205A (no)
BR (1) BR0011835A (no)
CA (1) CA2375265A1 (no)
CO (1) CO5190663A1 (no)
CZ (1) CZ20014458A3 (no)
DZ (1) DZ3055A1 (no)
EA (1) EA004264B1 (no)
EC (1) ECSP003538A (no)
EE (1) EE200100698A (no)
HR (1) HRP20010920A2 (no)
HU (1) HUP0201694A3 (no)
IL (1) IL146410A0 (no)
IS (1) IS6161A (no)
MA (1) MA26744A1 (no)
MX (1) MXPA02000033A (no)
NO (1) NO20016187D0 (no)
NZ (1) NZ515348A (no)
OA (1) OA11952A (no)
PA (1) PA8496701A1 (no)
PE (1) PE20010322A1 (no)
PL (1) PL352899A1 (no)
SK (1) SK18672001A3 (no)
TN (1) TNSN00137A1 (no)
TR (1) TR200103688T2 (no)
UY (1) UY26211A1 (no)
WO (1) WO2000078759A1 (no)
ZA (1) ZA200110387B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
MXPA05006271A (es) 2002-12-11 2006-01-30 Taro Pharmaceuticals Ind Ltd Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE69208877T2 (de) * 1991-05-31 1996-07-25 Pfizer Chinuclidinderivate
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
EP1187834A1 (en) 2002-03-20
TNSN00137A1 (fr) 2002-05-30
AR024411A1 (es) 2002-10-02
HUP0201694A2 (en) 2002-09-28
CO5190663A1 (es) 2002-08-29
AU4774500A (en) 2001-01-09
US6262067B1 (en) 2001-07-17
KR20020030280A (ko) 2002-04-24
BR0011835A (pt) 2002-03-05
ZA200110387B (en) 2002-12-19
AU767336B2 (en) 2003-11-06
EA004264B1 (ru) 2004-02-26
TR200103688T2 (tr) 2002-12-23
AP2001002367A0 (en) 2001-12-31
HRP20010920A2 (en) 2003-02-28
CN1390216A (zh) 2003-01-08
CZ20014458A3 (cs) 2002-03-13
IS6161A (is) 2001-11-13
CA2375265A1 (en) 2000-12-28
WO2000078759A1 (en) 2000-12-28
PA8496701A1 (es) 2002-07-30
SK18672001A3 (sk) 2002-08-06
EA200101179A1 (ru) 2002-06-27
MA26744A1 (fr) 2004-12-20
MXPA02000033A (es) 2002-07-02
NZ515348A (en) 2003-07-25
PL352899A1 (en) 2003-09-22
ECSP003538A (es) 2002-01-25
UY26211A1 (es) 2001-01-31
JP2003502425A (ja) 2003-01-21
IL146410A0 (en) 2002-07-25
NO20016187D0 (no) 2001-12-18
PE20010322A1 (es) 2001-03-14
DZ3055A1 (fr) 2004-03-27
OA11952A (en) 2006-04-13
BG106205A (bg) 2002-07-31
HUP0201694A3 (en) 2002-10-28
EE200100698A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
DK1349839T3 (da) Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
EE200000492A (et) Kristalsete orgaaniliste ühendite stabiilsed kindla kujuga osakesed
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO20004261D0 (no) 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister
NO20016187L (no) Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister
ZA989784B (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor.
IL144720A0 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
NO20014356L (no) Bifenylderivater som antagonister av neurokinin-1 reseptoren
NO994106D0 (no) Oksazolidiner som 5-HT2A-antagonister
DK0912556T3 (da) Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister
NO20006227D0 (no) Tetrahydroquiolinderivater som glycin antagonister
NO20015845L (no) Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister
NO995782L (no) Kvarternaere ammoniumforbindelser som tachykinin-antagonister
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO943101D0 (no) 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist
DK0882044T3 (da) 1,4-dihydropyridinforbindelser som bradykinin-antagonister
DK1207159T3 (da) Heteroaromatiske derivater som dopamin-D4-receptorantagonister
DK0994876T3 (da) Kvaternære ammoniumforbindelser som tachykinin-antagonister
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
AU2002354104A1 (en) Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
ZA200108302B (en) Substituted bicyclic heteroaryl compounds as integrin antagonists.
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik
DK1077942T3 (da) Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister
SI1155013T1 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application